Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Blood (2019) 134 (Supplement_1): 4028.

https://doi.org/10.1182/blood-2019-130223

Published: 2019

Journal Articles

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

John C. Reneau, MD, Steven R. Hwang, MD, Carlos A. Murga-Zamalloa, MD, Joseph J. Buggy, PhD, James W. Janc, PhD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2018-99-110554

Published: 2018

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2018-99-119944

Published: 2018

Journal Articles

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Janie Y Zhang, MD, Robert Briski, BS, Sumana Devata, MD, Mark S Kaminski, MD, Tycel Phillips, MD, Tera Mayer, NP, Nathanael G Bailey, MD, Ryan A Wilcox, MD PhD

Blood (2016) 128 (22): 4152.

https://doi.org/10.1182/blood.V128.22.4152.4152

Published: 2016

Journal Articles

Inhibition of IL2-Inducible T-Cell Kinase (ITK)-Mediated Chemoresistance By Ibrutinib in T-Cell Lymphoproliferative Disorders

Tianjiao Wang, PhD, Ye Lu, MD, Avery Polk, Carlos Murga Zamalloa, MD, Ryan A Wilcox, MD PhD

Blood (2015) 126 (23): 1467.

https://doi.org/10.1182/blood.V126.23.1467.1467

Published: 2015

Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Lisa Sproat, MD MSW, Jeanne Palmer, MD, James L. Slack, MD, Devinder Singh, MD, Eileen Gebhart, MSN, RN, ANP-BC, Emily Knight, RN, Shahrukh K. Hashmi, MD, Ryan A Wilcox, MD PhD, James M Bogenberger, PhD, Ruben A. Mesa, Aref Al-Kali, MD

Blood (2015) 126 (23): 1347.

https://doi.org/10.1182/blood.V126.23.1347.1347

Published: 2015

Journal Articles

Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders

Thirunavukkarasu Velusamy, PhD, Mark J. Kiel, MD PhD, Anagh A Sahasrabuddhe, PhD, Delphine C.M. Rolland, PharmD, PhD, Catherine A Dixon, PhD, Nathanael G. Bailey, MD, Bryan L Betz, PhD, Noah A. Brown, MD, Alexandra C Hristov, MD, Ryan A. Wilcox, MD PhD, Roberto N. Miranda, MD, L. Jeffrey Medeiros, MD, Yoon K Jeon, MD, Megan S Lim, MD PhD, Kojo S.J. Elenitoba-Johnson, MD

Blood (2014) 124 (21): 3032.

https://doi.org/10.1182/blood.V124.21.3032.3032

Published: 2014

Journal Articles

T-Cell Receptor Engagement Confers Resistance to Chemotherapy in T-Cell Lymphoproliferative Disorders

Tianjiao Wang, PhD, Avery Polk, BS, Ye Lu, MD, Ryan A Wilcox, MD PhD

Blood (2014) 124 (21): 2959.

https://doi.org/10.1182/blood.V124.21.2959.2959

Published: 2014

Journal Articles

The Absolute Lymphocyte to Monocyte Ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large B-Cell Lymphoma

Sumana Devata, MD, Nicholas Herrman, Robert Briski, Farahk Keyoumarsi, Daniel F Boyer, MD, Megan S Lim, MD PhD, Nathanael G. Bailey, MD, Ryan A. Wilcox, MD PhD

Blood (2014) 124 (21): 1646.

https://doi.org/10.1182/blood.V124.21.1646.1646

Published: 2014

Journal Articles

GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS

Tianjiao Wang, Ph.D., Andrew L. Feldman, David A Wada, MD, Ye Lu, MD, Avery Polk, BS, Robert Briski, BS, Kay M. Ristow, Thomas M Habermann, MD, Dafydd G Thomas, MD/Ph.D., Steven C. Ziesmer, Linda E Wellik, Thomas Lanigan, Ph.D., Thomas E Witzig, MD, Mark Pittelkow, MD, Nathanael G. Bailey, MD, Megan Lim, MD, PhD, Stephen M Ansell, M.D.Ph.D., Ryan A. Wilcox, MD, PhD

Blood (2013) 122 (21): 841.

https://doi.org/10.1182/blood.V122.21.841.841

Published: 2013

Journal Articles

The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma

Ryan A. Wilcox, MD, PhD, Kay M. Ristow, Thomas M. Habermann, MD, David J Inwards, MD, Ivana N. Micallef, MD, Patrick B. Johnston, Joseph P. Colgan, MD, Grzegorz S. Nowakowski, MD, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD, Svetomir N. Markovic, MD, PhD, Luis F. Porrata, MD

Blood (2011) 118 (21): 85.

https://doi.org/10.1182/blood.V118.21.85.85

Published: 2011

Journal Articles

In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics

Ryan A. Wilcox, MD, PhD, Kari Rabe, MS, Neil Kay, MD, Timothy G. Call, MD, Svetomir N. Markovic, MD, PhD, Luis F. Porrata, MD, Susan Schwager, Clive S. Zent, MD, Curtis A. Hanson, MD, Tait D. Shanafelt, MD

Blood (2011) 118 (21): 2835.

https://doi.org/10.1182/blood.V118.21.2835.2835

Published: 2011

Journal Articles

GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells

Ryan A. Wilcox, MD, PhD, Andrew L Feldman, MD, Kay Ristow, Thomas M. Habermann, MD, Steven Ziesmer, Linda Wellik, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD

Blood (2010) 116 (21): 4125.

https://doi.org/10.1182/blood.V116.21.4125.4125

Published: 2010

Journal Articles

The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma

Ryan A. Wilcox, MD, PhD, Kay Ristow, Thomas M. Habermann, MD, David James Inwards, MD, Ivana Micallef, MD, Patrick B Johnston, MD, PhD, Joseph Colgan, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD, Svetomir Markovic, MD, PhD, Luis Porrata, MD

Blood (2010) 116 (21): 3088.

https://doi.org/10.1182/blood.V116.21.3088.3088

Published: 2010

Journal Articles

GATA-3 Promotes IL-10 Production and Is An Adverse Prognostic Factor in Peripheral T-Cell Lymphoma Unspecified (PTCL-U).

Ryan A Wilcox, MD, PhD, Andrew L Feldman, MD, Steven C Ziesmer, Anne J. Novak, Thomas E. Witzig, MD, Stephen M Ansell

Blood (2009) 114 (22): 3929.

https://doi.org/10.1182/blood.V114.22.3929.3929

Published: 2009

Journal Articles

CD14 + hla-DR -/Lo Myeloid-Derived Suppressor Cells Express Immunosuppressive B7-H Family Members and Are Depleted Following Taxane-Based Chemotherapy in Melanoma.

Ryan A Wilcox, MD, PhD, Wendy K Nevala, Michael A Thompson, Thomas E Witzig, Stephen M Ansell, Svetomir N Markovic

Blood (2009) 114 (22): 464.

https://doi.org/10.1182/blood.V114.22.464.464

Published: 2009

Journal Articles

Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES)

Ryan A Wilcox, MD, PhD, Wada A David, MD, Andrew L. Feldman, Sherine F Elsawa, Deanna M Grote, Steven C Ziesmer, Anne J Novak, Mark R. Pittelkow, Thomas E. Witzig, Stephen M Ansell

Blood (2008) 112 (11): 378.

https://doi.org/10.1182/blood.V112.11.378.378

Published: 2008

Journal Articles

Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution’s Experience.

Ryan A. Wilcox, MD, PhD, Ahmet Dogan, MD, PhD, Kay Ristow, Joseph P. Colgan, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Svetomir N. Markovic, MD, PhD, Ivana N. M. Micallef, MD, Luis F. Porrata, MD, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD

Blood (2006) 108 (11): 3062.

https://doi.org/10.1182/blood.V108.11.3062.3062

Published: 2006

NARROW

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Inhibition of IL2-Inducible T-Cell Kinase (ITK)-Mediated Chemoresistance By Ibrutinib in T-Cell Lymphoproliferative Disorders

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders

T-Cell Receptor Engagement Confers Resistance to Chemotherapy in T-Cell Lymphoproliferative Disorders

The Absolute Lymphocyte to Monocyte Ratio at Diagnosis Further Stratifies Survival Based on Cell of Origin in Diffuse Large B-Cell Lymphoma

GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS

The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma

In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics

GATA-3 or T-Bet Expression In PTCL-U Identify High-Risk Patients with Poor Outcomes and Distinct Clinical Characteristics Suggesting Their Derivation From Specific Subsets of T Helper Cells

The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma

GATA-3 Promotes IL-10 Production and Is An Adverse Prognostic Factor in Peripheral T-Cell Lymphoma Unspecified (PTCL-U).

CD14 + hla-DR -/Lo Myeloid-Derived Suppressor Cells Express Immunosuppressive B7-H Family Members and Are Depleted Following Taxane-Based Chemotherapy in Melanoma.

Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES)

Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution’s Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only